On this episode of the J&J Innovation Podcast, we sit down with Artie Suckow, chief scientific officer of DTx Pharma, who explains what an "oligonucleotide therapeutic" is, and how they can potentially prevent disease-causing proteins from expressing themselves. We also talk to Jeff Friedman, who details his journey from investor to chief operations officer of DTx.
On this episode of the J&J Innovation Podcast, we sit down with Helge Zieler, founder and President of Primordial Genetics, about his journey from studying Malaria in Africa to unleashing the power of microbes in San Diego.
On this episode of the J&J Innovation Podcast, Caroline Baratz talks with Tim Mullen, Founder & CEO of Intheon, about building a platform to connect your brain through the cloud to any internet connected device, and how that can be used for a variety of health and wellness purposes, and even potentially space travel to distant planets.
William Hait, Johnson & Johnson's Global Head of External Innovation, discusses how he sees partnering with entrepreneurs and innovators as vital to bringing new ways to prevent, treat and cure diseases to patients.
On this episode of the J&J Innovation Podcast, Grace Castillo-Soyao, Founder & CEO of Self Care Catalysts, discusses how behavior science, big data and technology are converging to provide people with new and more personalize options for dealing with their health, and the healthcare system as a whole.
On this episode, we sit down for a conversation with Cat Oyler, Global Head, Strategy & Operations at Johnson & Johnson, for a more personal story about how innovation in the R&D space is improving lives of those around the world.
On today's episode we sit down with Josh Ghaim, head of Consumer R&D here at Johnson & Johnson. We discuss healthcare and beauty trends that we found at CES while also getting some insight into how J&J is approaching these new technologies and making a name for themselves at CES.
On this episode of the J&J Innovation Podcast, Bill Martin, CSO of Blackthorn Therapeutics, talks about the work they are doing to change the way we think about drug development, specifically as it pertains to treating brain disorders.
Cynthia Burzell was a scuba diver and graduate student when she made a discovery that would change her academic – and professional – future. Learn more about how Cynthia – along with her business partner, Marilyn Bruno – turned an underwater discovery into a company that’s trying to change how diseases are treated both near and far.
Seema Kumar re-joins Joe, Joe, and Brian to talk about the impact the Champions of Science program is already having. Plus, Dr. Paul Stoffels – Chief Scientific Officer at Johnson & Johnson – makes a surprise appearance to talk about why recognizing Champions of Science is so important for the future of healthcare.
On part 3 of our 3-part 'BIO Conference' Special we talk with Barry Springer to discuss how new ways of creating, developing, and funding drugs can speed our way into the age of individualized medicines.
On part 2 of our 3-part 'BIO Conference' Special we talk with Melinda Richter & Stephanie Robertson to discuss how new business and reimbursement models are needed to drive change and proactively engage with patients to provide a healthier future.